SAN DIEGO, Oct. 9 /PRNewswire-FirstCall/ -- Imagenetix, Inc. , announced today the appointment of Dr. Thomas Van Dyke to its Medical Advisory Board. Dr. Van Dyke will provide guidance to Imagenetix on their experimental compound, 1-TDC, for the treatment and prevention of periodontal disease. Dr. Van Dyke is Professor, Department of Periodontology and Oral Biology, Boston University Goldman School of Dental Medicine.
Dr. Van Dyke has extensive experience as a consultant to medical advisory boards having participated on boards spanning the spectrum from start-up to major pharmaceutical companies in the industry. In addition, he has participated as an investigator in numerous clinical trails of products seeking FDA approval.
Dr. Van Dyke received his D.D.S. (1973) from Case Western Reserve University; M.S. (1979) from SUNY at Buffalo in Oral Sciences and his Ph.D. (1982) from SUNY at Buffalo in Oral Biology. He is a Diplomate of the American Board of Periodontology (1989), and he received the IADR Award for Basic Research in Periodontology in 2001 and the Norton Ross Award for Excellence in Clinical Research in 2002. He serves on the editorial boards of Infection and Immunity (1989-present); Journal of Periodontology (1988-present), Journal of Periodontal Research (1987-present); Journal of Clinical Periodontology (1991- 1995), Journal of Public Health Dentistry (1991-1995), Current Opinions in Periodontology (1993). He served as President of the Periodontal Diseases Research Group of the IADR from 1991-1992. Dr. Van Dyke has authored/co- authored 200+ original articles, and numerous abstracts and book chapters. He is a member of the American/International Association of Dental Research, American Academy of Periodontology, American Dental Association, and a Diplomate of the American Board of Periodontology. His research interests are the structural and functional relationship of abnormalities of the inflammatory process with focus on regulation of phagocytic cells, in the etiology and pathogenesis of periodontal diseases. He is best known for his work on the pathways of resolution of inflammation and pathogenesis of periodontal diseases, neutrophil biology, and clinical research.
“We are very excited to add an individual of Dr. Van Dyke’s caliber and experience to our Medical Advisory Board”, said Mr. William Spencer, President of Imagenetix. “We believe his joining our Medical Advisory Board validates the success of our periodontal studies at Boston University. We also believe that he will be instrumental in helping us through the FDA process for our periodontal compound 1-TDC which we feel could be a major breakthrough in prevention of periodontal disease.”
About Imagenetix
Based in San Diego, California, Imagenetix, is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marked globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information, please visit, www.imagenetix.net.
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company’s products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.
CONTACT: Donald Radcliffe of Radcliffe & Associates, +1-212-605-0201; or
William P. Spencer, Chief Executive Officer of Imagenetix, Inc.,
+1-858-674-8450
Web site: http://www.imagenetix.net/
